Merck KGaA posts mixed data from their big PhIIb MS study on evobrutinib — spurring plenty of questions
Merck KGaA is posting some of their mid-stage data from a trial of their BTK inhibitor evobrutinib for multiple sclerosis. But despite a bold boast that the drug represents just how innovative their in-house R&D group is, the data are distinctly mixed.
On the primary endpoint, researchers claimed a clear win for the once-daily dose of 75 mg topping out with a statistically significant p value of 0.0015 in reducing the number of lesions measured among patients in the drug arm. The twice daily dose came in at 0.03 while the low dose failed. That’s not unusual.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.